Navigation Links
New Drug, Other Trends To Double Smoking Cessation and Addiction Treatments

With the advent of a possible new blockbuster drug and greater reimbursement levels for the treatment of nicotine, alcohol, and drug addictions, global sales of smoking cessation and addiction treatments are expected to rise from revenues of little over $1.1 billion in 2005 to more than $2.3 billion in 2010, according to Smoking Cessation and Addiction Treatments: A World Market Analysis, a new study released today from Kalorama Information.

Nicotine is clearly the most abused drug worldwide, with over 1.4 billion incidences, including 50 million users in the U.S. alone. Smoking cessation has continually become a particular focus of global health agencies, and the increasing high awareness of effective smoking cessation products have helped to drive market growth.

The market now dominated by GlaxoSmithKline with its Zyban smoking cessation treatment, and Schering-Plough / Reckitt Benckiser with their Suboxone/Subetex substance abuse treatment, is primed for a dramatic change as Pfizer moves into smoking cessation.

"We believe Pfizer's Chantix will acquire the largest share of the market, overtaking GlaxoSmithKline in smoking cessation, and leading all addiction treatments based on the superior effectiveness of Pfizer's product in clinical studies," notes Melissa Elder, the report's author. "To a more limited extent, new drugs in alcohol and substance abuse treatments will also change those markets."

Smoking Cessation and Addiction Treatments: A World Market Analysis includes world incidence and data for nicotine addiction, drug addiction, and alcohol abuse; current and forecasted revenues through 2010; current and forecasted market share with consideration of new players in the market; reviews of current products and new products in the pipeline; and key trends driving pharmaceutical treatments for smoking cessation and drug/alcohol addiction.


'"/>




Page: 1

Related medicine news :

1. FDA Approves New HIV Drug, Viread
2. FDA Approves New Arthritis Drug, Bextra
3. New Drug, Pleconaril speeds recovery from common cold
4. Herceptin Not A ‘Wonder’ Drug, Says The Lanct
5. NGO Files Pre-Grant Opposition Against Anti-HIV Drug, Combivir
6. Life-Saving Cancer Drug, Herceptin Will be Available Free for Breast Cancer Patients in Wales
7. Diabetes Drug, Exenatide, Good For Blood Sugar Levels and Weight Loss
8. FDA Gives Approval for Skin Cancer Drug, Zolinza
9. Was the Warning of a Severe Reaction To a Drug, Overlooked?
10. Anti-Craving Drug, Naltrexone Helps Women Quit Smoking
11. Teen Marijuana Use Does Not Predict Drug, Alcohol Abuse
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/28/2016)... ... April 28, 2016 , ... The Aging in Motion ... established an ICD-10-CM code for sarcopenia, giving it recognition for separate reporting and data ... October 1, 2016. , Sarcopenia is defined as a combination of low muscle mass ...
(Date:4/28/2016)... ... April 28, 2016 , ... ... affected by a health insurance co-operative bankruptcy to receive their prescription medications ... receive over 1,500 FDA-approved prescription medications from over 180 American pharmaceutical companies ...
(Date:4/28/2016)... (PRWEB) , ... April 28, 2016 , ... ... announced its latest offering, the Protocol Calendar Exchange , is officially open ... pre-built, pre-reviewed protocol calendars available for sites to download into their clinical trial ...
(Date:4/28/2016)... Vail, Colorado (PRWEB) , ... April 28, 2016 ... ... LaPrade, MD, PhD, Chief Medical Officer at the Steadman Philippon Research Institute ... Capitol Hill Day to raise awareness about the debilitating and costly musculoskeletal ...
(Date:4/28/2016)... ... April 28, 2016 , ... ... intelligent business communication applications and infrastructure for telecommunication service providers is pleased ... at Bestel’s Communications Network. The ACONYX Number Portability solution fully meets ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... MARLTON, N.J. , April 28, 2016   ... solutions, today announced that leading IT market research and ... Player " in the IDC MarketScape: Worldwide Pharmaceutical Track ... March 2016).  The report provides an assessment of the ... pharmaceutical track and trace software market. Logo ...
(Date:4/27/2016)... 2016  Hologic, Inc. (Nasdaq: HOLX ... the fiscal second quarter ended March 26, 2016.  ... increased 41.2%, and non-GAAP diluted EPS of $0.47 ... on a reported basis, and 6.3% on a ... another good quarter, highlighted by 14.6% growth in ...
(Date:4/27/2016)... -- Elekta today announced that its leading-edge ... focal point of seven scientific presentations at ESTRO 35, ... & Oncology, taking place April 29 - May 3. ... and a high-field MRI scanner with sophisticated software that ... in real time. The MR-linac is designed to improve ...
Breaking Medicine Technology: